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Abstract
Background: MicroRNAs (miRNAs) are endogenously expressed noncoding RNAs with important biological and
pathological functions. Although several studies have shown that microRNA-31 (miR-31) is obviously up-regulated
in colorectal cancer (CRC), there is no study on the functional roles of miR-31 in CRC.
Methods: Anti-miR™ miRNA 31 inhibitor (anti-miR-31) is a sequence-specific and chemically modified
oligonucleotide to specifically target and knockdown miR-31 molecule. The effect of anti-miR-31 transfection was
investigated by real-time PCR. HCT-116p53+/+ and HCT-116p53-/-colon cancer cells were treated by anti-miR-31 with
or without 5-fluorouracil (5-FU), cell proliferation was determined by MTT assay; apoptosis was detected by DAPI
staining; cell cycle was evaluated by flow cytometry; colony formation, migration and invasion assays were
performed to investigate the effect of suppression of miR-31 on the cell lines.
Results: Real-time PCR results showed that anti-miR-31 was efficiently introduced into the cells and reduced miR-
31 levels to 44.1% in HCT-116p53+/+ and 67.8% in HCT-116p53-/-cell line (p = 0.042 and 0.046). MTT results showed
that anti-miR-31 alone had no effect on the proliferation of HCT-116p53+/+ or HCT-116p53-/-. However, when
combined with 5-FU, anti-miR-31 inhibited the proliferation of the two cell lines as early as 24 h after exposure to
5-FU (p = 0.038 and 0.044). Suppression of miR-31 caused a reduction of the migratory cells by nearly 50%
compared with the negative control in both HCT-116p53+/+ and HCT-116p53-/-(p = 0.040 and 0.001). The invasive
ability of the cells were increased by 8-fold in HCT-116p53+/+ and 2-fold in HCT-116p53-/- (p = 0.045 and 0.009).
Suppression of miR-31 had no effect on cell cycle and colony formation (p > 0.05).
Conclusions: Suppression of miR-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and
invasion in HCT-116 colon cancer cells.
Background
MicroRNAs (miRNAs) are endogenous non-coding, sin-
gle-stranded RNAs of ~22 nucleotides which function as
post-transcriptional gene regulators [1]. More recently,
aberrant miRNAs expression profiles have emerged as
potential indicators of cancer development and progres-
sion, acting as major regulators of genes involved
in oncogenesis and tumor suppression [2]. MiRNAs
regulate their targets depending on the degree of com-
plementarity between miRNAs and targets, and result in
the degradation and/or translation inhibition of target
mRNAs [3]. These studies using bioinformatics algo-
rithms have revealed that a single miRNA might bind to
as many as 200 gene targets and that targets can be
diverse in their function; they include transcription fac-
tors, secreted factors, receptors and transporters. So,
miRNAs potentially control the expression of about
one-third of human mRNAs [4]. Thus, miRNAs add a
whole new layer of complexity by which large numbers* Correspondence: xiao-feng.sun@liu.se1Division of Oncology, Department of Clinical and Experiment Medicine,
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of genes and their biological processes can be broadly
regulated.
MicroRNA-31 (miR-31), located on chromosome
9p21.3, was first identified in HeLa cells [5]. More and
more evidence shows that miR-31 has different expres-
sion pattern in different cancers: it is up-regulated in
colorectal cancer (CRC) [6-10], head and neck squa-
mous cell carcinoma (HNSCC) [11], hepatocellular car-
cinoma [12], squamous cell carcinoma of tongue [13],
and lung cancer [14]; but it is down-regulated in inva-
sive urothelial carcinoma of the bladder [2], prostate
cancer [15], gastric cancer [16], breast cancer [17], and
serous ovarian cancer [18]. Although there is growing
evidence that miR-31 level varys among cancer types,
functional roles for miR-31 have yet to be defined.
Recent studies have shown that miR-31 expression is
specifically attenuated in metastatic breast cancer cell
lines and miR-31 inhibits breast cancer metastasis by
targeting multiple genes [17]; miR-31 is underexpressed
in serous ovarian carcinomas, and in a number of serous
cancer cell lines with a dysfunctional p53 pathway
(OVCAR8, OVCA433, and SKOV3), miR-31 overexpres-
sion inhibits proliferation and induces apoptosis; how-
ever, in other lines with functional p53 (HEY and
OVSAYO), miR-31 has no effect [18]. MiR-31 is up-
regulated in HNSCC, ectopic expression of miR-31
increases the oncogenic potential of HNSCC cells under
normoxic conditions in cell culture or tumor xenografts.
Conversely, blocking miR-31 expression reduces the
growth of tumor xenografts [11].
Although several studies have shown that miR-31 is
up-regulated in CRC, there is no study on the functional
roles of miR-31 in CRC, and little is known about the
role of miR-31 in modulating the tumor cell response to
5-fluorouracil (5-FU). The anti-miRNA inhibitor is a
sequence-specific and chemically modified oligonucleo-
tide to specifically target and knockdown miRNA mole-
cule, and has been applied to investigate miRNA
functions in several studies [19,20]. In the present study,
we applied anti-miR™ miRNA 31 inhibitor (anti-miR-31)
to knockdown miR-31 molecule in the HCT-116p53+/+
and HCT-116p53-/-colon cancer cells, and evaluated the
role of miR-31 in the response of HCT-116 to 5-FU.
The results suggest that suppression of miR-31 increases
sensitivity to 5-FU at an early stage, and affects cell
migration and invasion in HCT-116 colon cancer cells.
Methods
Cell culture and transient transfection
Human colon cancer cell lines HCT-116 with wild type
p53 (HCT-116p53+/+) or mutated p53 (HCT-116p53-/-)
used in this study were a kind gift from Dr. Bert Vogel-
stein (Johns Hopkins University, Baltimore, MD). Two
wild type p53 alleles in HCT-116 p53-/- have been
targeted by homologous recombination, resulting in a
mutated p53 with a 40 amino acid truncation, and the
HCT-116p53-/- cells do not express detectable wild type
p53 [21]. The two cell lines were cultured in McCoy’s
5A medium (Sigma-Aldrich, Stockholm, Sweden) sup-
plemented with 10% FBS (Invitrogen, Carlsbad, CA), 1%
PEST (Invitrogen) and 1.5 mM L-glutamine (Invitrogen).
Anti-miR™ miRNA 31 inhibitor (anti-miR-31) (Applied
Biosystems, Foster City, CA) or Anti-miR™ negative con-
trol (Applied Biosystems) were transfected at a final
concentration of 100 nM using the siPORT™ NeoFX™
Transfection Agent (Applied Biosystems) according to
the manufacture’s protocol.
RNA extraction and quantitative reverse transcription-PCR
analysis
Total RNA, inclusive of the small RNA fraction, was
extracted from cells using mirVana™ miRNA Isolation
Kit (Ambion Inc., Austin, TX) according to the manu-
facture’s protocol. The RNA concentration was quanti-
fied using a ND-100 Spectrophotometer (Nanodrop
technologies, Wilmington, DE). TaqMan MicroRNA
assays (Applied Biosystems) were used to quantify miR-
31 expression, and RNU6B (Applied Biosystems) was
used as the endogenous control.
Gene-specific reverse transcription (RT) for miR-31 and
RUN6B using about 200 ng of purified total RNA, 0.15 μL
of 100 mM dNTPs (with dTTP), 1.5 μL 50 u/μL Multi-
Scribe Reverse Transcriptase, 1.5 μL 10 × RT Buffer, 0.188
μL RNase Inhibitor, 3.0 μL 5 × TaqMan microRNA RT
Primer and 4.162 μL nuclease free water. Fifteen microliter
reaction was incubated for 30 min at 16°C, 30 min at 42°C,
and 5 min at 85°C to inactivate reverse transcriptase. Real-
time PCR reaction, including 1.33 μL of RT product, 7.67
μL nuclease free water, 10 μL TaqMan 2 × Universal PCR
master mix (Applied Biosystems) and 1 μL TaqMan
microRNA Assay containing PCR primers and TaqMan
probes, was run in triplicate on the ABI Prism 7500 HT
Sequence Detection System (Applied Biosystems) at 95°C
for 10 min followed by 40 cycles at 95°C for 15s and 60°C
for 1 min. MiR-31 expression change was normalized to
RNU6B, and calculated using the 2-ΔΔCt method. Each test
was repeated in triplicate.
MTT assay
Cell proliferation was measured by the 3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) (Sigma-Aldrich) assay. 5-FU (Sigma-Aldrich)
stock solution of 80 mM was prepared in dimethyl sulf-
oxide (DMSO) (Sigma-Aldrich). For the 5-FU dose-
response curve, cells were plated at a density of 4.8 ×
103 cells/well, and incubated for 24 h. 5-FU was added
to the wells at a final concentration of 2, 4, 6, 8 and
10 μM, and continued to incubate for another 48 h.
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The final DMSO concentration was always less than
0.1%. Then, 20 μL of 5 mg/mL solution of MTT in PBS
was added to each well. The plates were incubated for
another 4 h at 37°C. The precipitate was solubilized in
100% DMSO 150 μL/well, and shaken for 10 min.
Absorbance of each well was measured on a microplate
reader (Anthos ht III, Anthos Labtec Instruments
GmbH, Wals, Austria) at a wave length of 490 nm.
To investigate the effect of miR-31 on the response of
HCT-116 cells to 5-FU, cells were transfected with 100
nM of either anti-miR-31 or Anti-miR™ negative control
in 96-well plates at a density of 2 × 103 cells/well, and
incubated for 24 h. 5-FU was added to the well at a
final concentration of 8 μM. At the indicated time
points, cell viability was tested by MTT assay. Each test
was repeated in triplicate.
DAPI staining
At the given time point, the cells in culture were centri-
fuged to spin the apoptotic cells to the bottom of the
plate and were trypsinized with TrypLE (Invitrogen). The
pellet was resuspended in PBS and cells were centrifuged
on to a glass slide with a Shandon Cytospin® 2 Cytocen-
trifuge (Thermo ScientiWc, Waltham, MA). The cells on
the slides were fixed with buffered formalin for 10 min,
washed in ice cold PBS for 10 min and then stained/
mounted with VECTASHIELD® HardSet™ Mounting
Medium with diamidino-2-phenylindole (DAPI) (Vector
Laboratories, Burlingame, CA). The cells were morpholo-
gically examined by two independent investigators in a
fluorescence microscope with UV light and judged as
either apoptotic or non-apoptotic (areas of about 200
cells were counted). Each test was repeated in triplicate.
Cell cycle analysis
Cells were transfected with 100 nM of either anti-miR-
31 or negative control in 24-well plates at a density of
2.7 × 104 cells/well, and incubated for 48 h. Cells were
trypsinized and prepared for cell cycle analysis using the
Vindelöv protocol with propidium iodine (PI) for DNA
staining [22]. Cell cycle analysis was performed using a
FACScan (Becton-Dickinsson, San José, CA). The data
were analyzed and calculated by ModFit LT for Mac V
3.1 (Verity Software House, Inc., Topsham, ME). Each
test was repeated in triplicate.
Colony formation assay
Log-phase cells were transfected with 100 nM of either
anti-miR-31 or negative control, seeded in the 6-well
plates with 2 ml medium (500 cells/well), and incubated at
37°C in a humidified incubator. Plates were initially exam-
ined microscopically to confirm that only single cells with-
out clumps had been plated. Five days after plating,
colonies were fixed with 4% formaldehyde and stained
with 5% Giemsa in 95% ethanol. Colonies were visualized
with Leica microscope (Leica Microsysytems wetzlar
GmbH, Germany) and pictures were taken with Olympus
SC20 camera and soft imaging system (Olympus soft ima-
ging solution GmbH, Germany). The colonies with a dia-
meter of > 0.3 mm were counted under light microscope
at 4 × magnification, and the colony forming efficiency
(CFE) was determined by the percentage of colonies per
well. Each test was repeated in triplicate.
Cell migration and invasion assay
Cells were transfected with 100 nM of either anti-miR-
31 or negative control, and incubated for 24 h, then the
cells were starved by incubating for 12 h in serum-free
medium. For the migration assay, 4 × 104 cells were
resuspended in 300 μL serum-free medium and added
into the upper chamber of the QCM™ 24 Well Colori-
metric Cell Migration Assay (Millipore Corporation,
Billerica, MA); For the invasion assay, 8 × 104 cells in
300 μL serum-free medium were added into the upper
chamber of the Cell Invasion Assay Kit (Millipore Cor-
poration). 500 μL of 10% FBS medium was added to the
lower chamber. Thereafter the cells were incubated 16 h
for migration assay and 48 h for invasion assay. Then
the cells/media were carefully removed from the top
side of the insert by pipetting out the remaining cell
suspension, a cotton-tipped swab was used to gently
remove non-migratory or non-invasive cells from the
interior of the insert. The insert was stained and the
images from 5 representative fields of each membrane
were taken. The amount of migratory and invasive cells
in the lower chamber was counted. Each test was
repeated three or four times.
Statistical analysis
All data were expressed as the mean ± SEM from at
least three independent experiments. Student’s t-test for
two groups or one-way analysis of variance (ANOVA)
and post hoc multiple comparisons (LSD test) for three
or four groups were performed to evaluate the statistical
significance using the SPSS 11.5 statistical software
package (SPSS, Inc., Chicago, IL). Tests were two-sided,
and p < 0.05 was considered as statistically significant.
Results
Sensitivity of HCT-116 cells to 5-FU
We initially evaluated 5-FU cytotoxicity in both HCT-
116p53+/+ and HCT-116p53-/- cell lines. Plasma concentra-
tion of 5-FU was more than 5 μM in patients subjected
to continuous drug infusion at a constant rate of 450-966
mg/m2/day [23,24]. Borralho et al. used 8 μM 5-FU to
treat HCT-116, and regarded it as a clinically relevant
concentration [25]. Our result showed that the optical
density (OD) value decreased in a dose-dependent
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manner after supplementation with 5-FU for 48 h
(Figure 1, p < 0.001). Exposure to 0.1% DMSO solvent
alone did not significantly alter the OD value (data not
shown). So we used 8 μM 5-FU for the following
experiments.
Suppression of miR-31 increased sensitivity to 5-FU in
HCT-116 cells
TaqMan real-time PCR revealed that anti-miR-31 trans-
fection significantly reduced miR-31 levels to 44.1% in
HCT-116p53+/+ cell line (p = 0.042), and 67.8% in HCT-
116p53-/- (p = 0.046) compared with negative control
(Figure 2), confirming that anti-miR-31 was efficiently
introduced into the cells and knocked down miR-31.
MTT results showed that anti-miR-31 alone had no
effect on the proliferation of either HCT-116p53+/+ or
HCT-116p53-/- cell lines (p > 0.05). However, when com-
bined with 5-FU, anti-miR-31 inhibited the proliferation
of both cell lines as early as 24 h after exposure to 5-
FU. As shown in Figure 3, at the 24 h timepoint, the
OD value of the negative control and 5-FU combined
treatment group was lower than either negative control
or anti-miR-31 group, but the difference was not statis-
tically significant (p = 0.382 and 0.221). When we com-
bined anti-miR-31 with 5-FU, the OD value became the
lowest among the four groups, and the difference
between the anti-miR-31 plus 5-FU treatment group and
the negative control or anti-miR-31 group was significant
(p < 0.05). With prolongation of exposure (≥ 48 h), 5-FU
exhibited a strong inhibition on the proliferation of both
HCT-116p53+/+ and HCT-116p53-/- cell lines (p < 0.01),
and the effect of anti-miR-31 on cell proliferation was
covered by 5-FU.
We used DAPI staining to detect the apoptotic cells
after 24 h exposure to 5-FU. ANOVA analysis showed
that apoptosis in different treatment groups were signifi-
cantly different in both cell lines (p = 0.002 and 0.001),
and, as shown in Figure 4, the apoptosis rate in the anti-
miR-31 plus 5-FU group was the highest among the four
different treatment groups of either cell lines (8.8% ±
0.8% in HCT-116p53+/+ and 18.4% ± 1.9% HCT-116p53-/-).
Since 5-FU alone strongly inhibited the proliferation
of HCT-116 cells in vitro, in the following experiments,
we mainly focused on the anti-miR-31 and negative con-
trol groups in order to investigate miR-31 function.
Suppression of miR-31 had no effects on cell cycle and
colony formation in HCT-116 cells
We examined the effect of anti-miR-31 on HCT-116 cell
cycle and colony formation. Suppression of miR-31 did
not change cell cycle distribution either in HCT-116p53+/+
or HCT-116p53-/- cells (Figure 5). Although suppression of
miR-31 slightly reduced the colony forming efficiency,
there was no statistical significance in both cell lines
(Figure 6, p > 0.05).
Suppression of miR-31 decreased migration but increased
invasion in HCT-116 cells
We performed in vitro migration and invasion assays.
Suppression of miR-31 significantly decreased cell
Figure 1 5-FU induced cytotoxicity in HCT-116p53+/+ and HCT-116p53-/- cell lines in a dose-dependent manner at 48 h (p < 0.001).
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migration ability in both HCT-116 cell lines. Although
there were slight variations between different cell pas-
sages used in independent experiments, suppression of
miR-31 persistently decreased migration by nearly 50%
in both HCT-116p53+/+ and HCT-116p53-/- cells when
the results were normalized to negative control
transfected cells (p = 0.040 and 0.001, Figure 7). The
invasive cells were increased by 8-fold in HCT-116p53+/+
cell line, and 2-fold in HCT-116p53-/- cell line (p =
0.045 and 0.009, Figure 8). The number of invasive
cells were obviously less than migratory cells in both
cell lines.
Figure 2 Suppression of miR-31 expression by anti-miR-31 as detected by TaqMan real-time PCR. Compared with negative control, miR-
31 was reduced to 44.1% in HCT-116p53+/+ (p = 0.042) and 67.8% in HCT-116p53-/- (p = 0.046) cell line.
Figure 3 MTT assay for cell viability at different time points. Anti-miR-31 alone had no effect on the proliferation of either HCT-116p53+/+ or
HCT-116p53-/- cell line (p > 0.05), but when combined with 5-FU, anti-miR-31 inhibited the proliferation of both cell lines as early as 24 h after
exposure to 5-FU, i.e., the optical density (OD) value of anti-miR-31 + 5-FU group was the lowest among the four groups, and the difference
between anti-miR-31 + 5-FU group and negative control or anti-miR-31 group was significant (p < 0.05).
Wang et al. BMC Cancer 2010, 10:616
http://www.biomedcentral.com/1471-2407/10/616
Page 5 of 11
Discussion
We were particularly interested in investigating the
effect of miR-31 on the cellular response to 5-FU. Our
results showed that although the suppression of miR-31
alone had no effect on cell proliferation, it did increase
the sensitivity to 5-FU in HCT-116 cells as early as 24 h
after exposure. At the same time point, combined treat-
ment by 5-FU plus negative control did not significantly
reduce the viability of the cells. With prolongation of
exposure to 5-FU, both the combined groups, either 5-
FU plus negative control or anti-miR-31, significantly
reduced the cells viability. The apoptosis rate in the
anti-miR-31 plus 5-FU group was the highest among the
four different treated groups of either cell line, indicat-
ing that the anti-miR-31 plus 5-FU inhibited the cells
proliferation partly through the apoptotic mechanism.
Figure 4 DAPI staining for detecting the apoptotic cells at 24 h after exposure to 5-FU. Apoptosis rate in anti-miR-31 + 5-FU group was
the highest among the four different treatment groups of either cell line (8.8% ± 0.8% in HCT-116p53+/+ and 18.4% ± 1.9% HCT-116p53-/-).
Figure 5 Propidium iodine staining for detecting the cell cycle. Suppression of miR-31 did not change cell cycle distribution either in HCT-
116p53+/+ or HCT-116p53-/- cells.
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However, the increase in the sensitivity of HCT-116
cells to 5-FU is quite modest and further studies are
required to validate this phenomenon on more colon
cancer cell lines, and even on other kinds of cancer cell
lines.
Accumulating evidence suggests that miRNAs could
be key players in regulation of tumor cell invasion and
metastasis [26]. Our previous study showed that miR-31
expression was up-regulated in CRC compared to nor-
mal mucosa, and tumors which invaded adjacent tissues
or organs had more miR-31 expression than those lim-
ited to the wall of the colon and rectum [6]. It was rea-
sonable to speculate that miR-31 might affect the
migration or invasion in CRC.
In the present study, the suppression of miR-31 caused
a reduction of the migratory cells by nearly 50% com-
pared with the negative control in both HCT-116p53+/+
and HCT-116p53-/- cell lines. This was in line with a
provious study that blockage of miR-31 expression signif-
icantly decreased viability and migration in a HNSCC cell
line [11]. Unexpectedly, our results showed that the inva-
sive cells were increased by 8-fold in HCT-116p53+/+ cell
line, and 2-fold in HCT-116p53-/- cell line. In HCT-116
cells, suppression of miR-31 decreased migration but
increased invasion in vitro, this phenomenon might be
partly explained by the fact that the migration assay
detected the cell motility through an 8 μm pore polycar-
bonate membrane; however, the invasion assay not only
evaluated cell motility but also the ability of tumor cells
to invade through a basement membrane model
(a reconstituted basement membrane matrix of proteins,
including laminin and type IV collagen, derived from the
Eangelbreth Holm-Swarm (EHS) mouse tumor [27]). So
those cells that were capable of completing the entire
process represented only a small subpopulation of the
cells compared with the migration assay.
MiR-31 is down-regulated in serous ovarian cancer
and miR-31 overexpression inhibits proliferation and
induces apoptosis in a number of serous cancer cell
lines with a dysfunctional p53 pathway. However, in
other lines with functional p53, miR-31 has no effect
[18]. On the other hand, overexpression of miR-31 sup-
presses metastasis in breast cancer cell lines, and does
not affect proliferation in vitro [17]. In CRC, miR-31
was significantly up-regulated [6] and our present data
showed that suppression of miR-31 increased the sensi-
tivity of HCT-116 cells to 5-FU at an early stage,
affected cell migration and invasion. Taken together, it
seems that not only the expression but also the func-
tions of miR-31 are cancer specific.
MiRNAs have been reported to be directly transacti-
vated by p53; equally, p53 and components of its pathway
have been shown to be targeted by miRNA thereby affect-
ing p53 activities [28]. We asked whether miR-31 had a
relationship with p53 in CRC. The HCT-116p53+/+ and
HCT-116p53-/- cell lines are suitable to investigate the rela-
tionship between miRNAs and p53. Our results showed
that the suppression of miR-31 had almost the same
effects on cell cycle and colony formation. However, as for
the cell invasion, it had a stronger effect on HCT-116p53
+/+ than HCT-116p53-/- cell line, the apoptotic rate in
HCT-116p53+/+ was lower than that in HCT-116p53-/- cell
Figure 6 Suppression of miR-31 had no effect on colony forming efficiency in either cell line (p > 0.05).
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Figure 7 Suppression of miR-31 decreased cell migration. (A) Boyden chamber with 8 μm pore polycarbonate membrane was used for the
migration assay. The chamber was stained and analyzed by photography, the stained cells were migratory cells in the lower chamber. (B) The
migratroy cells decreased nearly 50% in both HCT-116p53+/+ and HCT-116p53-/- cells when they were normalized to negative control transfected
cells (p = 0.040 and 0.001).
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Figure 8 Suppression of miR-31 increased cell invasion. (A) Boyden chamber with 8 μm pore polycarbonate membrane coated with
Matrigel was used for the invasion assay. The chamber was stained and analyzed by photography, the stained cells were invasive cells in the
lower chamber. (B) The invasive cells increased by 8-fold in HCT-116p53+/+ cell line (p = 0.045), and 2-fold in HCT-116p53-/- cell line (p = 0.009).
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line, suggesting miR-31 affected the colon cancer partly in
a p53 dependent manner. In serous ovarian carcinomas,
miR-31 is underexpressed, and, in a number of serous can-
cer cell lines with a dysfunctional p53 pathway, miR-31
overexpression inhibits proliferation and induces apopto-
sis; however, in other lines with functional p53, miR-31
has no effect [18]. Taken together, it suggests that miR-31
may regulate different processes in different cancers,
dependent on the cell of origin of the cancer.
The lack of knowledge about the targets for miR-31 in
CRC hampers a full understanding on the biological
functions of miR-31. Bioinformatic analysis reveals that
miR-31 can control the expression of more than one
hundred genes (miRBASE, http://microrna.sanger.ac.uk).
It may be expected that the targets of miR-31 belong to
the class of tumor suppressor genes or genes encoding
proteins with potential tumor suppressor functions.
BAP1, a tumor suppressor gene that functions in the
BRCA1 growth pathway [29]; HIF1AN, inhibits HIF1A
transcriptional activity [30]; MAPK transduction protein
such as MAP4K5; RAS homologues RAB14, RAB6B, and
RASA1 were found as potential targets of miR-31. MiR-
31 is also up-regulated in HNSCC and lung cancer.
More recently, factor-inhibiting hypoxia-inducible factor
(FIH) was experimentally verified as the target of miR-
31 in HNSCC cell and the tumor-suppressive genes,
large tumor suppressor 2 (LATS2) and PP2A regulatory
subunit B alpha isoform (PPP2R2A) were the targets of
miR-31 in lung cancer [11,14]. Whether these experi-
mentally verified targets in other cancers are validated
in CRC or there are other special targets in CRC need
to be answered by further studies.
Conclusions
Our findings suggest that suppression of miR-31 increases
sensitivity to 5-FU at an early stage, and affects cell migra-
tion and invasion in HCT-116 colon cancer cells.
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